

## DAFTAR PUSTAKA

- Aberg, J.A., Lacy, C., Armstrong, L., Goldman, M., dan Lance, L.L., 2009. *Drug Information Handbook*, 17th edition. ed. American Pharmacist Association, Washington D. C.
- Abou-Ismaïl, M.Y., Diamond, A., Kapoor, S., Arafah, Y., dan Nayak, L., 2020. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. *Thrombosis Research*, **194**: 101–115.
- Adam, C.D., Anger, K.A., Greenwood, B.C., dan Fanikos, J., 2012. Antithrombotic Pharmacotherapy, dalam: *Irwin and Rippe's Intensive Care Medicine, Chapter 110*. Lippincott, Williams, and Wilkins, Philadelphia, PA, hal. 1224–1242.
- Al-Samkari, H., Karp Leaf, R.S., Dzik, W.H., Carlson, J.C.T., Fogerty, A.E., Waheed, A., dkk., 2020. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood*, **136**: 489–500.
- American Diabetes Association, 2010. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, **33**: S62–S69.
- Anonim, 2022, *Drug Interaction Report*, [https://www.drugs.com/interactions-check.php?drug\\_list=243-0,705-0,978-0](https://www.drugs.com/interactions-check.php?drug_list=243-0,705-0,978-0), diakses pada tanggal 23 Mei 2022.
- Arslan, Y., Yilmaz, G., Dogan, D., Hasirci, M., Cetindogan, H., Ocal, N., dkk., 2021. The effectiveness of early anticoagulant treatment in Covid-19 patients. *Phlebology*, **36**: 384–391.
- Aursulesei, V. dan Costache, I.I., 2019. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. *Clinical Cardiology*, **42**: 774–782.
- Barras, M. dan Legg, A., 2017. Drug dosing in obese adults. *Australian Prescriber*, **40**: 189–193.
- Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., dkk., 2020. Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine*, **383**: 1813–1826.
- Belen-Apak, F.B. dan Sarıalioglu, F., 2020. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. *Journal of Thrombosis and Thrombolysis*, **50**: 278–280.
- Biswas, M., Rahaman, S., Biswas, T.K., Haque, Z., dan Ibrahim, B., 2021. Association of Sex, Age, and Comorbidities with Mortality in COVID-19

Patients: A Systematic Review and Meta-Analysis. *Intervirology*, **64**: 36–47.

Buendgens, L., Koch, A., dan Tacke, F., 2016. Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis. *World Journal of Critical Care Medicine*, **5**: 57–64.

Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, W., Susilo, A., dkk., 2021. *Pedoman Tatalaksana Covid-19*, 3rd ed. PDPI, PERKI, PAPDI, PERDATIN, IDAI, Jakarta.

Cardillo, G., Viggiano, G.V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., dkk., 2021. Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. *Journal of Blood Medicine*, **12**: 69–75.

Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C., dan Di Napoli, R., 2021. Features, Evaluation, and Treatment of Coronavirus (COVID-19), dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).

Cejka, V., De Vries, L.A., Smorenberg-Schoorl, M.E., Van Daatselaar, J.J., Borst, J.G.G., dan Majoor, C.L.H., 1960. EFFECT OF HEPARINOID AND SPIROLACTONE ON THE RENAL EXCRETION OF SODIUM AND ALDOSTERONE. *The Lancet*, , Originally published as Volume 1, Issue 7119 **275**: 317–319.

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., dkk., 2020. Clinical and immunological features of severe and moderate coronavirus disease 2019. *Journal of Clinical Investigation*, **130**: 2620–2629.

Chen, Y., Klein, S.L., Garibaldi, B.T., Li, H., Wu, C., Osevala, N.M., dkk., 2021. Aging in COVID-19: Vulnerability, immunity and intervention. *Ageing Research Reviews*, **65**: 101205.

Chisholm-Burns, M., Schwinghammer, T., Wells, B., Malone, P., DiPiro, J., Kolesar, J., dkk., 2016. *Pharmacotherapy Principles and Practice, Fourth Edition*, 4th edition. ed. McGraw-Hill Education / Medical, New York.

COVID-19 Treatment Guidelines Panel, 2021. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. *National Institutes of Health*.

Crowther, M.A. dan Warkentin, T.E., 2008. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. *Blood*, **111**: 4871–4879.

Cui, S., Chen, S., Li, X., Liu, S., dan Wang, F., 2020. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, 10.1111/jth.14830.

- Dobesh, P.P. dan Trujillo, T.C., 2020. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. *Pharmacotherapy*, 10.1002/phar.2465.
- Feng, Z., Li, Q., Zhang, Y., Wu, Z., Dong, X., dan Ma, H., 2020. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly*, **2**: 113–122.
- Frederiksen, S., Ekelund, M., Rothpfeffer, R., Peterli, R., dan Hedenbro, J., 2014. Low-Molecular-Weight-Heparin as Thromboprophylaxis: a Dosage Problem in Obese Patients. *Journal of Research in Obesity*, 1–8.
- Frediansyah, A., Nainu, F., Dhama, K., Mudatsir, M., dan Harapan, H., 2021. Remdesivir and its antiviral activity against COVID-19: A systematic review. *Clinical Epidemiology and Global Health*, **9**: 123–127.
- Garcia, D.A., Baglin, T.P., Weitz, J.I., dan Samama, M.M., 2012. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, **141**: e24S-e43S.
- Garg, S., Kim, L., Whitaker, M., O'Halloran, A., Cummings, C., Holstein, R., dkk., 2020. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR. Morbidity and mortality weekly report*, **69**: 458–464.
- Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R., dkk., 2008. Prevention of Venous Thromboembolism. *Chest*, **133**: 381S-453S.
- Gelzleichter, T.R., 2013. Early Characterization of Biosimilar Therapeutics, dalam: *Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics*. Elsevier, Amsterdam, hal. 185–210.
- Gemmati, D., Bramanti, B., Serino, M.L., Secchiero, P., Zauli, G., dan Tisato, V., 2020. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? *International Journal of Molecular Sciences*, **21**: 3474.
- Giefing-Kröll, C., Berger, P., Lepperdinger, G., dan Grubeck-Loebenstien, B., 2015. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. *Aging Cell*, **14**: 309–321.

- Gouin-Thibault, I., Pautas, E., dan Siguret, V., 2005. Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose. *Drug Safety*, **28**: 333–349.
- Guan, W., Liang, W., Zhao, Y., Liang, H., Chen, Zi-sheng, Li, Y., dkk., 2020. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *European Respiratory Journal*, **55**: 2000547.
- Guarner, J., 2020. Three Emerging Coronaviruses in Two Decades. *American Journal of Clinical Pathology*, **153**: 420–421.
- Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., dkk., 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Military Medical Research*, **7**: 11.
- Han, P.Y., Duffull, S.B., Kirkpatrick, C.M.J., dan Green, B., 2007. Dosing in Obesity: A Simple Solution to a Big Problem. *Clinical Pharmacology & Therapeutics*, **82**: 505–508.
- Haqqani, O.P., Iafrati, M.D., dan Freedman, J.E., 2013. Pharmacology of Antithrombotic Drugs, dalam: *Vascular Medicine: A Companion to Braunwald's Heart Disease*. Saunders, Philadelphia, hal. 94–109.
- He, X., Yao, F., Chen, J., Wang, Y., Fang, X., Lin, X., dkk., 2021. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. *Scientific Reports*, **11**: 1830.
- Hirsh, J., 1998. Low-Molecular-Weight Heparin: A Review of the Results of Recent Studies of the Treatment of Venous Thromboembolism and Unstable Angina. *Circulation*, **98**: 1575–1582.
- Hirsh, J., Anand, S.S., Halperin, J.L., dan Fuster, V., 2001. Mechanism of Action and Pharmacology of Unfractionated Heparin. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **21**: 1094–1096.
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., dkk., 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, **181**: 271–280.e8.
- Holford, P., Carr, A.C., Jovic, T.H., Ali, S.R., Whitaker, I.S., Marik, P.E., dkk., 2020. Vitamin C—An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. *Nutrients*, **12**: 3760.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., dkk., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, **395**: 497–506.

- Huang, W., Berube, J., McNamara, M., Saksena, S., Hartman, M., Arshad, T., dkk., 2020. Lymphocyte Subset Counts in COVID -19 Patients: A Meta-Analysis. *Cytometry Part A*, **97**: 772–776.
- Iaccarino, G., Grassi, G., Borghi, C., Ferri, C., Salvetti, M., Volpe, M., dkk., 2020. Age and Multimorbidity Predict Death Among COVID-19 Patients. *Hypertension*, **76**: 366–372.
- Ingle, R. dan Agarwal, A.S., 2014. A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety--a review. *Carbohydrate polymers*, .
- Johns Hopkins University and Medicine, 2021. *Covid-19 Dashboard by the Center for System Science and Engineering (CSSE)*, <https://coronavirus.jhu.edu/map.html>., diakses pada tanggal 20 Desember 2021.
- Joly, B.S., Siguret, V., dan Veyradier, A., 2020. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Medicine*, **46**: 1603–1606.
- Karyono, D.R. dan Wicaksana, A.L., 2020. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *Journal of Community Empowerment for Health*, **3**: 77.
- Kemenkes RI, 2016. *Peraturan Menteri Kesehatan Tentang Pedoman Indonesian Case Base Groups (INA-CBG) Dalam Pelaksanaan Jaminan Kesehatan Nasional*. Kementerian Kesehatan RI, Jakarta.
- Kemenkes RI, 2020. *Pedoman Pencegahan Dan Pengendalian Coronavirus Disease (Covid-19) (5th Ed.)*. Kementerian Kesehatan RI, Jakarta.
- Klok, F.A., Kooiman, J., Huisman, M.V., Konstantinides, S., dan Lankeit, M., 2015. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. *European Respiratory Journal*, **45**: 201–210.
- Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., dkk., 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research*, **191**: 145–147.
- Kollias, A., Kyriakoulis, K.G., Dimakakos, E., Poulakou, G., Stergiou, G.S., dan Syrigos, K., 2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. *British Journal of Haematology*, **189**: 846–847.

- Kumar, A., Arora, A., Sharma, P., Anikhindi, S.A., Bansal, N., Singla, V., dkk., 2020. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, **14**: 535–545.
- Laporte, S., Liotier, J., Bertoletti, L., Kleber, F.-X., Pineo, G.F., Chapelle, C., dkk., 2011. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients: Enoxaparin vs. UFH in the prevention of VTE. *Journal of Thrombosis and Haemostasis*, **9**: 464–472.
- Levi, M., Thachil, J., Iba, T., dan Levy, J.H., 2020. Coagulation abnormalities and thrombosis in patients with COVID-19. *The Lancet Haematology*, **7**: e438–e440.
- Li, X., Geng, M., Peng, Y., Meng, L., dan Lu, S., 2020. Molecular immune pathogenesis and diagnosis of COVID-19. *Journal of Pharmaceutical Analysis*, **10**: 102–108.
- Li, X., Zhong, X., Wang, Y., Zeng, X., Luo, T., dan Liu, Q., 2021. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. *PLOS ONE*, **16**: e0250602.
- Lin, Z., Phyu, W.H., Phyu, Z.H., dan Mon, T.Z., 2021. The Role of Steroids in the Management of COVID-19 Infection. *Cureus*, **13**: e16841.
- Liu, J., Li, J., Arnold, K., Pawlinski, R., dan Key, N.S., 2020. Using heparin molecules to manage COVID-2019. *Research and Practice in Thrombosis and Haemostasis*, **4**: 518–523.
- Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., dkk., 2020. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis Research*, **191**: 9–14.
- Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X., dkk., 2020. D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. *BioMed Research International*, **2020**: 1–10.
- Lopes, R.D., de Barros e Silva, P.G.M., Furtado, R.H.M., Macedo, A.V.S., Bronhara, B., Damiani, L.P., dkk., 2021. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet (London, England)*, **397**: 2253–2263.
- Lucijanic, M., Krecak, I., Soric, E., Sedinic, M., Sabljic, A., Derek, L., dkk., 2021. Thrombocytosis in COVID-19 patients without myeloproliferative



neoplasms is associated with better prognosis but higher rate of venous thromboembolism. *Blood Cancer Journal*, **11**: 189.

Mahboobipour, A.A. dan Baniyasi, S., 2020. Clinically important drug–drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management. *Drug Metabolism and Personalized Therapy*, **0**: 20200145.

McBane, R.D., Torres Roldan, V.D., Niven, A.S., Pruthi, R.K., Franco, P.M., Linderbaum, J.A., dkk., 2020. Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. *Mayo Clinic Proceedings*, **95**: 2467–2486.

McGarry, L.J., Stokes, M.E., dan Thompson, D., 2006. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. *Thrombosis Journal*, **4**: 17.

Mercola, J., Grant, W.B., dan Wagner, C.L., 2020. Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity. *Nutrients*, **12**: 3361.

Mrityunjaya, M., Pavithra, V., Neelam, R., Janhavi, P., Halami, P.M., dan Ravindra, P.V., 2020. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. *Frontiers in Immunology*, **11**: 570122.

Mulloy, B., Hogwood, J., Gray, E., Lever, R., dan Page, C.P., 2016. Pharmacology of Heparin and Related Drugs. *Pharmacological Reviews*, **68**: 76–141.

Musoke, N., Lo, K.B., Albano, J., Peterson, E., Bhargav, R., Gul, F., dkk., 2020. Anticoagulation and bleeding risk in patients with COVID-19. *Thrombosis Research*, **196**: 227–230.

Nadar, S.K., Goyal, D., Shantsila, E., Banerjee, P., dan Lip, G.Y., 2009. Fondaparinux: an overview. *Expert Review of Cardiovascular Therapy*, **7**: 577–585.

Nadkarni, G.N., Lala, A., Bagiella, E., Chang, H.L., Moreno, P.R., Pujadas, E., dkk., 2020. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. *Journal of the American College of Cardiology*, **76**: 1815–1826.

Nagge, J., Crowther, M., dan Hirsh, J., 2002. Is Impaired Renal Function a Contraindication to the Use of Low-Molecular-Weight Heparin? *Archives of Internal Medicine*, **162**: 2605–2609.

Nguyen, M.C., Pride, Y.B., dan Michael Gibson, C., 2010. Anticoagulation, dalam: *Cardiac Intensive Care*. Saunders, Philadelphia, PA, hal. 443–451.

- Nishimoto, Y., Yachi, S., Takeyama, M., Tsujino, I., Nakamura, J., Yamamoto, N., dkk., 2022. The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. *Journal of Cardiology*, .
- Nutescu, E.A., Burnett, A., Fanikos, J., Spinler, S., dan Wittkowsky, A., 2016. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, **41**: 15–31.
- Olivas-Martínez, A., Cárdenas-Fragoso, J.L., Jiménez, J.V., Lozano-Cruz, O.A., Ortiz-Brizuela, E., Tovar-Méndez, V.H., dkk., 2021. In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. *PLOS ONE*, **16**: e0245772.
- Oster, J.R., Singer, I., dan Fishman, L.M., 1995. Heparin-induced aldosterone suppression and hyperkalemia. *The American Journal of Medicine*, **98**: 575–586.
- Oudkerk, M., Büller, H.R., Kuijpers, D., van Es, N., Oudkerk, S.F., McLoud, T., dkk., 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. *Radiology*, **297**: E216–E222.
- Paranjpe, I., Fuster, V., Lala, A., Russak, A.J., Glicksberg, B.S., Levin, M.A., dkk., 2020. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. *Journal of the American College of Cardiology*, **76**: 122–124.
- Parasher, A., 2021. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgraduate Medical Journal*, **97**: 312.
- Parker, K.L. dan Brunton, L.L., 2008. *Goodman and Gilman's Manual of Pharmacology and Therapeutics by Laurence Brunton*. McGraw-Hill Medical, New York.
- Pemda DIY, 2021. *Yogyakarta Tanggap COVID-19, Informasi Covid-19 Daerah Istimewa Yogyakarta*. <https://corona.jogjapro.go.id/> diakses pada tanggal 20 Desember 2021.
- Pranata, R., Lim, M.A., Huang, I., Raharjo, S.B., dan Lukito, A.A., 2020. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. *Journal of the Renin-Angiotensin-Aldosterone System*, **21**: 147032032092689.



- Pratiwi, A.D.E. dan Adhityasmara, D., 2021. Gambaran Penggunaan Antikoagulan pada Pasien Covid-19 di Salah Satu Rumah Sakit Rujukan Covid-19 di Kota Semarang. *Sebatik*, **25**: 442–448.
- Rentsch, C.T., Beckman, J.A., Tomlinson, L., Gellad, W.F., Alcorn, C., Kidwai-Khan, F., dkk., 2021. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. *BMJ*, n311.
- Reynolds, H.R., Adhikari, S., Pulgarin, C., Troxel, A.B., Iturrate, E., Johnson, S.B., dkk., 2020. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. *The New England Journal of Medicine*, NEJMoa2008975.
- Rosovsky, R.P., Sanfilippo, K.M., Wang, T.F., Rajan, S.K., Shah, S., Martin, K.A., dkk., 2020. Anticoagulation practice patterns in COVID-19: A global survey. *Research and Practice in Thrombosis and Haemostasis*, **4**: 969–983.
- Russo, V., Cardillo, G., Viggiano, G.V., Mangiacapra, S., Cavalli, A., Fontanella, A., dkk., 2020. Thromboprophylaxis With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study. *Frontiers in Medicine*, **7**: 569567.
- Saurabh, A., Dey, B., Raphael, V., Deb, P., Khonglah, Y., dan Tiewsoh, I., 2021. Role of Coagulation Profile in Predicting Disease Severity Among Patients of COVID-19. *Cureus*, .
- Schiavone, M., Gasperetti, A., Mancone, M., Curnis, A., Mascioli, G., Mitacchione, G., dkk., 2021. Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience. *International Journal of Cardiology*, **323**: 276–280.
- Schiffrin, E.L., Flack, J.M., Ito, S., Muntner, P., dan Webb, R.C., 2020. Hypertension and COVID-19. *American Journal of Hypertension*, hpa057.
- Shakoor, H., Feehan, J., Al Dhaheri, A.S., Ali, H.I., Platat, C., Ismail, L.C., dkk., 2021. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19? *Maturitas*, **143**: 1–9.
- Sharma, A., Tiwari, S., Deb, M.K., dan Marty, J.L., 2020. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. *International Journal of Antimicrobial Agents*, **56**: 106054.
- Shoeb, M. dan Fang, M.C., 2013. Assessing Bleeding Risk in Patients Taking Anticoagulants. *Journal of thrombosis and thrombolysis*, **35**: 312–319.
- Smith, J.C., Sausville, E.L., Girish, V., Yuan, M.L., Vasudevan, A., John, K.M., dkk., 2020. Cigarette Smoke Exposure and Inflammatory Signaling

Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract. *Developmental Cell*, **53**: 514-529.e3.

Smythe, M.A., Burns, C., Liu, Q., dan Garwood, C.L., 2022. Potential Dexamethasone–Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID? *Annals of Pharmacotherapy*, **56**: 319–329.

Soni, M., Gopalakrishnan, R., Vaishya, R., dan Prabu, P., 2020. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, **14**: 2245–2249.

Spyropoulos, A.C., Anderson, F.A., FitzGerald, G., Decousus, H., Pini, M., Chong, B.H., dkk., 2011. Predictive and associative models to identify hospitalized medical patients at risk for VTE. *Chest*, **140**: 706–714.

Stockley, I.H. dan Baxter, K. (Editor), 2008. *Stockley's Drug Interactions*, 8th ed. ed. Pharmaceutical Press, London.

Surendra, H., Elyazar, I.R., Djaafara, B.A., Ekawati, L.L., Saraswati, K., Adrian, V., dkk., 2021. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *The Lancet Regional Health - Western Pacific*, **9**: 100108.

Tang, N., Li, D., Wang, X., dan Sun, Z., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, **18**: 844–847.

Tatro, D.S., 2009. *Drug Interaction Facts*. Wolters Kluwer Health, San Carlos.

Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., dkk., 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *Journal of Thrombosis and Haemostasis*, **18**: 1023–1026.

Wang, J., Saguner, A.M., An, J., Ning, Y., Yan, Y., dan Li, G., 2020. Dysfunctional Coagulation in COVID-19: From Cell to Bedside. *Advances in Therapy*, **37**: 3033–3039.

Wang, X., Fang, X., Cai, Z., Wu, X., Gao, X., Min, J., dkk., 2020. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. *Research*, **2020**: 1–17.

Wells, B., DiPiro, J., Schwinghammer, T., dan DiPiro, C., 2008. *Pharmacotherapy Handbook, Seventh Edition*, 7th edition. ed. McGraw-Hill Medical, New York.

- Wells, B.G., DiPiro, J., Schwinghammer, T.L., dan DiPiro, C.V., 2014. *Pharmacotherapy Handbook, Ninth Edition*, 9th edition. ed. McGraw-Hill, New York.
- Wenham, C., Smith, J., dan Morgan, R., 2020. COVID-19: the gendered impacts of the outbreak. *The Lancet*, **395**: 846–848.
- Whelton, P.K., Carey, R.M., Aronow, W.S., Casey, D.E., Collins, K.J., Dennison Himmelfarb, C., dkk., 2018. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*, **71**: .
- WHO, 2014. *Infection Prevention and Control of Epidemic and Pandemic Prone Acute Respiratory Infections in Healthcare – WHO Guidelines*, [https://www.who.int/csr/bioriskreduction/infection\\_control/publication/en/](https://www.who.int/csr/bioriskreduction/infection_control/publication/en/), diakses pada tanggal 10 Oktober 2021.
- WHO, 2020. *Transmisi SARS-CoV-2: Implikasi terhadap Kewaspadaan Pencegahan Infeksi*, [https://www.who.int/docs/default-source/searo/indonesia/covid19/transmisi-sars-cov-2---implikasi-untuk-terhadap-kewaspadaan-pencegahan-infeksi---pernyataan-keilmuan.pdf?sfvrsn=1534d7df\\_4](https://www.who.int/docs/default-source/searo/indonesia/covid19/transmisi-sars-cov-2---implikasi-untuk-terhadap-kewaspadaan-pencegahan-infeksi---pernyataan-keilmuan.pdf?sfvrsn=1534d7df_4), diakses pada tanggal 10 Oktober 2021.
- WHO, 2021. *WHO Coronavirus (COVID-19) Dashboard*, <https://covid19.who.int>, diakses pada tanggal 20 Desember 2021.
- Xie, J., Zhong, R., Wang, W., Chen, O., dan Zou, Y., 2021. COVID-19 and Smoking: What Evidence Needs Our Attention? *Frontiers in Physiology*, **12**: .
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., dkk., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*, **8**: 420–422.
- Xue, Y., Sun, S., Cai, J., Zeng, L., Wang, Shihui, Wang, Suhuai, dkk., 2020. Effects of ACEI and ARB on COVID-19 patients: A meta-analysis. *Journal of the Renin-Angiotensin-Aldosterone System: JRAAS*, **21**: 1470320320981321.
- Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., dkk., 2020. Thrombocytopenia and its association with mortality in patients with COVID-19. *Journal of Thrombosis and Haemostasis*, **18**: 1469–1472.

- Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., dkk., 2020. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. *Journal of Intensive Care*, **8**: 49.
- Yormaz, B., Ergün, D., Tülek, B., Ergün, R., Arslan, U., dan Kanat, F., 2021. Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease. *Turkish Journal of Medical Sciences*, **51**: 28–38.
- Zhai, Z., Li, C., Chen, Y., Gerotziafas, G., Zhang, Z., Wan, J., dkk., 2020. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. *Thrombosis and Haemostasis*, **120**: 937–948.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., dkk., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, **395**: 1054–1062.
- Zhou, Y., Chi, J., Lv, W., dan Wang, Y., 2021. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19). *Diabetes/Metabolism Research and Reviews*, **37**: .